Short Interest in InflaRx N.V. (NASDAQ:IFRX) Expands By 28.0%

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,270,000 shares, an increase of 28.0% from the May 15th total of 992,100 shares. Currently, 2.3% of the company's stock are short sold. Based on an average daily trading volume, of 467,200 shares, the short-interest ratio is currently 2.7 days.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Guggenheim raised their price target on shares of InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th. Oppenheimer reduced their price objective on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research note on Thursday, May 29th. Raymond James Financial cut InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price for the company. in a research note on Thursday, May 29th. Cantor Fitzgerald assumed coverage on InflaRx in a report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $6.60.

InflaRx Price Performance

Shares of IFRX traded up $0.03 during midday trading on Wednesday, reaching $0.80. The stock had a trading volume of 392,602 shares, compared to its average volume of 285,301. The company has a market cap of $53.57 million, a price-to-earnings ratio of -0.97 and a beta of 1.29. The company's fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $1.72. InflaRx has a 1-year low of $0.71 and a 1-year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. InflaRx had a negative return on equity of 64.17% and a negative net margin of 33,362.70%. On average, sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IFRX. 683 Capital Management LLC lifted its stake in InflaRx by 26.8% during the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock worth $2,678,000 after purchasing an additional 555,000 shares during the last quarter. Woodline Partners LP acquired a new stake in InflaRx during the first quarter worth approximately $766,000. Northern Trust Corp lifted its position in shares of InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company's stock worth $1,647,000 after buying an additional 634,045 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of InflaRx in the 4th quarter valued at $1,576,000. Finally, DAFNA Capital Management LLC acquired a new position in shares of InflaRx in the 1st quarter valued at $459,000. Hedge funds and other institutional investors own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.